Giménez E, Torres I, Albert E, Piñana J-L, Hernández-Boluda J-C, Solano C, et al. Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis. Am J Transpl. 2019;19:2479–94.
Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009;22:76–98. Table of Contents
Article CAS PubMed PubMed Central Google Scholar
de la Cámara R. CMV in hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis. 2016;8:e2016031.
Article PubMed PubMed Central Google Scholar
Dziedzic M, Sadowska-Krawczenko I, Styczynski J. Risk factors for cytomegalovirus infection after allogeneic hematopoietic cell transplantation in malignancies: proposal for classification. Anticancer Res. 2017;37:6551–6.
Jakharia N, Howard D, Riedel DJ. CMV infection in hematopoietic stem cell transplantation: prevention and treatment strategies. Curr Treat Options Infect Dis. 2021;13:123–40.
Article PubMed PubMed Central Google Scholar
Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113:5711–9.
Article CAS PubMed PubMed Central Google Scholar
Gagelmann N, Ljungman P, Styczynski J, Kröger N. Comparative efficacy and safety of different antiviral agents for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Biol Blood Marrow Transpl. 2018;24:2101–9.
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44.
Article CAS PubMed Google Scholar
Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e260–e272.
Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Einsele H, et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis. 2014;59:473–81.
Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87–91.
Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019;68:1420–6.
Article CAS PubMed Google Scholar
Green ML, Leisenring W, Stachel D, Pergam SA, Sandmaier BM, Wald A, et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2012;18:1687–99.
Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3:e119–127.
Article PubMed PubMed Central Google Scholar
Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11:284–92.
Article CAS PubMed Google Scholar
Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, et al. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2019;25:369–81.
FDA Approves PREVYMIS (Letermovir). https://www.accp1.org/ACCP1/5Publications_and_News/FDA_Approves_PREVYMIS__Letermovir_.aspx (accessed 1 May2022).
EMA. Prevymis. European Medicines Agency. 2018.https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis (accessed 1 May2022).
Brissot E, Alsuliman T, Beauvais D, Bonnin A, Mear J-B, Souchet L, et al. [Antiviral prophylaxis for CMV, HSV/VZV and HBV in allogeneic hematopoietic cell transplantation in adult patients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer. 2020;107:S1–S6.
Olson AL, Politikos I, Brunstein C, Milano F, Barker J, Hill JA, et al. Guidelines for infection prophylaxis, monitoring and therapy in cord blood. Transplant Transpl Cell Ther. 2021;27:359–62.
Royston L, Royston E, Masouridi-Levrat S, Vernaz N, Chalandon Y, Van Delden C, et al. Letermovir primary prophylaxis in high-risk hematopoietic cell transplant recipients: a matched cohort study. Vaccines (Basel). 2021;9:372.
Malagola M, Pollara C, Polverelli N, Zollner T, Bettoni D, Gandolfi L, et al. Advances in CMV management: a single center real-life experience. Front Cell Dev Biol. 2020;8:534268.
Article PubMed PubMed Central Google Scholar
Alsumali A, Chemaly RF, Graham J, Jiang Y, Merchant S, Miles L, et al. Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective. J Med Virol. 2021;93:3786–94.
Article CAS PubMed Google Scholar
Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, et al. A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. Clin Infect Dis. 2020;70:1525–33.
Article CAS PubMed Google Scholar
Su Y, Stern A, Karantoni E, Nawar T, Han G, Zavras P et al. Impact of letermovir primary Cytomegalovirus (CMV) prophylaxis on 1-year mortality after allogeneic hematopoietic cell transplantation (HCT): a retrospective cohort study. Clin Infect Dis. 2022;: ciab1064.
Pande A, Dubberke ER. Cytomegalovirus infections of the stem cell transplant recipient and hematologic malignancy patient. Infect Dis Clin North Am. 2019;33:485–500.
Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2002;8:117–30.
Emery V, Zuckerman M, Jackson G, Aitken C, Osman H, Pagliuca A, et al. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol. 2013;162:25–39.
Article CAS PubMed Google Scholar
Alexander BT, Hladnik LM, Augustin KM, Casabar E, McKinnon PS, Reichley RM, et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy. 2010;30:554–61.
Article CAS PubMed PubMed Central Google Scholar
Alsuliman T, Kitel C, Dulery R, Guillaume T, Larosa F, Cornillon J, et al. Cytotect®CP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: a multicenter retrospective study. Bone Marrow Transpl. 2018;53:1328–35.
Erard V, Guthrie KA, Seo S, Smith J, Huang M, Chien J, et al. Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis. 2015;61:31–39.
Article CAS PubMed PubMed Central Google Scholar
Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, et al. Off-the-shelf virus-specific T cells to treat bk virus, human herpesvirus 6, cytomegalovirus, epstein-barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017;35:3547–57.
Article CAS PubMed PubMed Central Google Scholar
Meesing A, Razonable RR. New developments in the management of cytomegalovirus infection after transplantation. Drugs. 2018;78:1085–103.
Article CAS PubMed Google Scholar
Pei X-Y, Liu X-F, Zhao X-Y, Lv M, Mo X-D, Chang Y-J, et al. Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation. Cell Mol Immunol. 2022;19:482–91.
Article CAS PubMed Google Scholar
Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis. 2021: ciab988.
留言 (0)